Glucagon · source year
6 selected, source-linked Glucagon records carrying a 2024 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
6 selected records.
2 represented types.
6 distinct public records.
Cited chronology
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 204468 with status AP dated 2024-12-12, and names glucagon among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03965130 at 2026-07-30T18:38:25.510Z. Its registry update date was 2024-11-26, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2024-18898, attributed to FDA and its parent HHS department, on 2024-08-23. Its official title is “Final Decision on the Proposal To Refuse To Approve a New Drug Application for ITCA 650,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Glucagon.
Source: Federal Register via GovInfo ↗
Regulatory
The Federal Register published notice 2024-17649, attributed to FDA and its parent HHS department, on 2024-08-08. Its official title is “Determination That DELATESTRYL (Testosterone Enanthate) Injection, 200 Milligrams/Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06498063 at 2026-07-30T18:42:56.616Z. Its registry update date was 2024-07-12, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2024-12065, attributed to FDA and its parent HHS department, on 2024-06-03. Its official title is “Pfizer, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon.
Source: Federal Register via GovInfo ↗